ATE524732T1 - Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg - Google Patents

Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg

Info

Publication number
ATE524732T1
ATE524732T1 AT07751467T AT07751467T ATE524732T1 AT E524732 T1 ATE524732 T1 AT E524732T1 AT 07751467 T AT07751467 T AT 07751467T AT 07751467 T AT07751467 T AT 07751467T AT E524732 T1 ATE524732 T1 AT E524732T1
Authority
AT
Austria
Prior art keywords
myd88
plant alkaloids
signaling
tlr
status
Prior art date
Application number
AT07751467T
Other languages
English (en)
Inventor
Gil Mor
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE524732T1 publication Critical patent/ATE524732T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07751467T 2006-02-23 2007-02-23 Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg ATE524732T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77630406P 2006-02-23 2006-02-23
US78816806P 2006-03-31 2006-03-31
PCT/US2007/004707 WO2007100650A2 (en) 2006-02-23 2007-02-23 Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway

Publications (1)

Publication Number Publication Date
ATE524732T1 true ATE524732T1 (de) 2011-09-15

Family

ID=38349578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07751467T ATE524732T1 (de) 2006-02-23 2007-02-23 Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg

Country Status (4)

Country Link
US (1) US7985538B2 (de)
EP (1) EP1996935B1 (de)
AT (1) ATE524732T1 (de)
WO (1) WO2007100650A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP2316032A1 (de) 2008-08-20 2011-05-04 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur vorhersage des ansprechens auf eine antikrebsbehandlung mit einem agonisten von tlr7 oder einem agonisten von tlr8
WO2010135671A1 (en) * 2009-05-22 2010-11-25 The Usa, As Represented By The Secretary, Dpt Of Health And Human Services Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy
SG182522A1 (en) 2010-01-27 2012-08-30 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
US20190077874A1 (en) * 2017-09-13 2019-03-14 National Tuberous Sclerosis Association, Inc. Methods and compositions for the treatment of tuberous sclerosis
CN111643677B (zh) * 2020-05-26 2023-06-27 四川省肿瘤医院 一种包封TLR4/MyD88信号通路拮抗剂的纳米脂质体及其制备方法和应用
CN115715802A (zh) * 2022-09-09 2023-02-28 上海市普陀区中心医院 MyD88抑制剂在制备治疗乳腺癌和逆转乳腺癌紫杉醇耐药的药物中的应用
CN117418013A (zh) * 2023-12-19 2024-01-19 四川省肿瘤医院 用于检测卵巢癌细胞MyD88基因5'URR CpG岛甲基化水平的引物、方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054814A1 (en) 2003-11-26 2005-06-16 Yale University Apoptosis-based evaluation of chemosensitivity in cancer patients
US20090169472A1 (en) 2005-10-12 2009-07-02 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders

Also Published As

Publication number Publication date
US7985538B2 (en) 2011-07-26
EP1996935B1 (de) 2011-09-14
WO2007100650A2 (en) 2007-09-07
WO2007100650A3 (en) 2008-04-03
EP1996935A2 (de) 2008-12-03
US20090220427A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
ATE524732T1 (de) Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg
Hasanabady et al. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
Dai et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma
Argyriou et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Pinto-Garcia et al. Berberine inhibits cell growth and mediates caspase-independent cell death in human pancreatic cancer cells
Félix et al. Antileishmanial activity of new thiophene–indole hybrids: Design, synthesis, biological and cytotoxic evaluation, and chemometric studies
ATE490306T1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
MX2011012267A (es) Metodos para proveer pruebas de medicina personalizadas ex vivo en cuanto a neoplasmas hematologicos.
WO2008006517A3 (en) Prediction of breast cancer response to taxane-based chemotherapy
RU2014119150A (ru) Модулирование некоторых тирозинкиназ
NZ627443A (en) Biological markers for identifying patients for treatment with vegf antagonists
EA201792650A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
CY1116697T1 (el) Συνδετες sigma για την προληψη ή τη θεραπεια πονου που εχει προκληθει απο χημειοθεραπεια
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
Xu et al. MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury
EP1888089A4 (de) Ex-vivo-genexpression in vollblut als modell für die beurteilung von individueller variation gegenüber nahrungszusätzen
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
ATE550661T1 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörper
Lu et al. Anticancer drug combinations, studies from different pathways
WO2008014420A3 (en) Non-human animal models for b-cell non-hodgkin's lymphoma and uses thereof
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia
AR069639A1 (es) Composicion de nanoparticulas con superficie modificada
Roell et al. Synergistic chemotherapy drug response is a genetic trait in lymphoblastoid cell lines
Ko et al. Antinociceptive effect of phenyl N-tert-butylnitrone, a free radical scavenger, on the rat formalin test

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties